# Study of a Live rNDV Based Vaccine Against COVID-19

> **NCT04871737** · PHASE1 · COMPLETED · sponsor: **Laboratorio Avi-Mex, S.A. de C.V.** · enrollment: 91 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** Recombinant NDV Vectored Vaccine for SARS-CoV-2

## Key facts

- **NCT ID:** NCT04871737
- **Lead sponsor:** Laboratorio Avi-Mex, S.A. de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-20
- **Primary completion:** 2022-08-21
- **Final completion:** 2022-09-30
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2023-07-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04871737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04871737, "Study of a Live rNDV Based Vaccine Against COVID-19". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04871737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*